Varella Andrea Yasbek Monteiro, Fukuda Juliana Maria, Teivelis Marcelo Passos, Pinheiro Lucas Lembrança, Mendes Cynthia de Almeida, Kauffman Paulo, Campos José Ribas Milanez de, Wolosker Nelson
Division of Vascular and Endovascular Surgery, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Division of Thoracic Surgery, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Rev Assoc Med Bras (1992). 2018 Feb;64(2):127-132. doi: 10.1590/1806-9282.64.02.127.
The association of osmidrosis and hyperhidrosis often causes emotional and social problems that may impair the patients' quality of life. The purpose of our study was to analyze the therapeutic results of oxybutynin and topical agents in 89 patients with both osmidrosis and hyperhidrosis.
We conducted an observational study at two specialized centers of hyperhidrosis between April 2007 and August 2013. Eighty-nine (89) patients with both osmidrosis and hyperhidrosis were treated with oxybutynin and topical agents. Patients were evaluated before treatment and at 3 and 6 weeks after treatment started, by using the Quality of Life Questionnaire and the Sweating Evolution Scale.
Before treatment, 98% of the patients presented with poor or very poor quality of life. After six weeks of treatment, 70% stated their quality of life as being slightly better or much better (p<0.001) and nearly 70% of the patients experienced a moderate or great improvement in sweating and malodor. Improvement in osmidrosis was significantly greater when the axillary region was the first most disturbing site of hyperhidrosis.
There was a significant improvement in quality of life and a reduction in sweating and malodor after six weeks of treatment with topical agents and oxybutynin in patients with both hyperhidrosis and osmidrosis. Therefore, clinical treatment should be considered before invasive techniques.
臭汗症与多汗症的关联常常引发情绪和社交问题，可能会损害患者的生活质量。我们研究的目的是分析奥昔布宁和外用药物对89例同时患有臭汗症和多汗症患者的治疗效果。
2007年4月至2013年8月期间，我们在两个多汗症专科中心进行了一项观察性研究。89例同时患有臭汗症和多汗症的患者接受了奥昔布宁和外用药物治疗。在治疗开始前以及治疗开始后3周和6周，使用生活质量问卷和出汗变化量表对患者进行评估。
治疗前，98%的患者生活质量较差或非常差。治疗六周后，70%的患者表示他们的生活质量略有改善或有很大改善（p<0.001），近70%的患者出汗和异味有中度或显著改善。当腋窝区域是多汗症最困扰的首要部位时，臭汗症的改善更为显著。
对于同时患有多汗症和臭汗症的患者，使用外用药物和奥昔布宁治疗六周后，生活质量有显著改善，出汗和异味减少。因此，在采用侵入性技术之前应考虑临床治疗。
